Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.75 |
| ▸ | LTA4H | P09960 | 2/20 | 0.70 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29237868 | 0.92 | TAAR1 (0.65) | TAAR1LTA4HPLA2G2ASMN1; SMN2CYP19A1 | |
| SCHEMBL7866458 | 0.89 | TAAR1 (0.62) | TAAR1LTA4HPLA2G2ASMN1; SMN2CYP19A1 | |
| SCHEMBL3183362 | 0.87 | TAAR1 (0.60) | TAAR1LTA4HPLA2G2ASMN1; SMN2CYP19A1 | |
| SCHEMBL3158699 | 0.87 | TAAR1 (0.60) | TAAR1LTA4HPLA2G2ASMN1; SMN2CYP19A1 | |
| SCHEMBL4584910 | 0.87 | TAAR1 (0.60) | TAAR1LTA4HPLA2G2ASMN1; SMN2CYP19A1 | |
| SCHEMBL23905132 | 0.87 | LTA4H (0.64) | TAAR1LTA4HPLA2G2A | |
| SCHEMBL14017120 | 0.87 | TAAR1 (0.60) | TAAR1LTA4HPLA2G2ASMN1; SMN2CYP19A1 | |
| SCHEMBL1010863 | 0.87 | TAAR1 (0.60) | TAAR1LTA4HPLA2G2ASMN1; SMN2MEN1 | |
| SCHEMBL304730 | 0.87 | TAAR1 (0.60) | TAAR1LTA4HPLA2G2ASMN1; SMN2CYP19A1 | |
| SCHEMBL1784442 | 0.87 | TAAR1 (0.60) | TAAR1LTA4HPLA2G2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668968-B1 | Polymeric ascorbic acid devices for tissue regeneration | COVIDIEN LP (US) | 2019-08-14 | — | — | EP | claimed |
| US-20210292464-A1 | SELF-HEALING COMPOSITION | CENTRE NAT RECH SCIENT (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-11-03 | — | — | US | disclosed |
| WO-2015095406-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999064033-A9 | PHOSPHODIESTERASE-V MODULATOR DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-3933737-A | SULFUR-CONTAINING ORGANOTIN COMPOUNDS AND NON-SULFUR-CONTAINING ORGANOTIN COMPOUNDS | KABEL-UND METALLWERKE GUTEHOFFNUNGSHUTTE AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | TAAR1 2430/4885LTA4H 355/4885PLA2G2A 151/4885 |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | TAAR1 4635/4885LTA4H 463/4885PLA2G2A 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.